Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Phase 2RecruitingNCT00722228

Hadassah Medical Organization50 enrolled

Overview

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Colorectal Cancer Ovarian Cancer Gastric Cancer Breast Cancer Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney * Above 18 years of age * Failure of at least one chemotherapy protocol * Clinical performance status of ECOG 0,1 * Absolute neutrophil count greater than 1000/mm3 * Serum ALT/AST less than three times the upper limit of normal * Serum creatinine less than or equal to 1.6 mg/dl. * Must be able to understand and sign the Informed Consent document Exclusion Criteria: * Below 18 years of age * Women who are pregnant * Life expectancy of less than three months

Central Contacts

Hani Steinberg, R.N. B.A.

CONTACT

: 00 972 50 7874292 hanis@hadassah.org.il

Tamar Peretz, MD

CONTACT

00 972 2 6777825 tamary@hadassah.org.il

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Overview

Conditions

Interventions

Eligibility

Locations (1)

Central Contacts